

Deok-Hwan Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8536525/publications.pdf>

Version: 2024-02-01

133
papers

1,970
citations

304743

22
h-index

302126

39
g-index

134
all docs

134
docs citations

134
times ranked

3209
citing authors

#	ARTICLE	IF	CITATIONS
1	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 389-400.	10.7	285
2	Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 746-756.	1.4	160
3	Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2011, 47, 1312-1318.	2.8	82
4	Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1597-1604.	2.0	76
5	Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. <i>Annals of Hematology</i> , 2013, 92, 471-479.	1.8	69
6	The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. <i>Leukemia Research</i> , 2009, 33, 665-670.	0.8	62
7	Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2007, 82, 1-5.	4.1	51
8	Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 118-125.	2.0	49
9	High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era. <i>Leukemia Research</i> , 2016, 42, 1-6.	0.8	49
10	DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 61-70.	2.0	43
11	A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. <i>Oncotarget</i> , 2017, 8, 41538-41548.	1.8	39
12	Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 1013-1020.	4.1	37
13	Naïve CD8+ T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF- β 2 immunosuppression in the tumor microenvironment. <i>Scientific Reports</i> , 2016, 6, 28208.	3.3	36
14	18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 107-115.	6.4	34
15	Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. <i>Haematologica</i> , 2015, 100, e351-e353.	3.5	31
16	The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2009, 88, 425-432.	1.8	28
17	Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. <i>BMC Cancer</i> , 2015, 15, 198.	2.6	28
18	Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic. <i>Chonnam Medical Journal</i> , 2015, 51, 1.	0.9	27

#	ARTICLE	IF	CITATIONS
19	Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 212.	1.7	27
20	Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. <i>Annals of Hematology</i> , 2016, 95, 301-310.	1.8	26
21	Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. <i>Annals of Hematology</i> , 2010, 89, 795-801.	1.8	25
22	<i>OCT-1</i> , <i>ABCB1</i> , and <i>ABCG2</i> Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib. <i>Chonnam Medical Journal</i> , 2014, 50, 102.	0.9	25
23	Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. <i>Blood Research</i> , 2015, 50, 19.	1.3	24
24	Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. <i>BMC Cancer</i> , 2016, 16, 613.	2.6	24
25	Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2471-2478.	2.0	24
26	STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma. <i>Blood Research</i> , 2017, 52, 293.	1.3	23
27	Treatment Outcome and Prognostic Factors in Patients with Precursor B and T Lymphoblastic Lymphoma. <i>Blood</i> , 2008, 112, 3601-3601.	1.4	20
28	Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. <i>Oncotarget</i> , 2018, 9, 4961-4968.	1.8	19
29	Polymorphisms in DNA Repair Genes and MDR1 and the Risk for Non-Hodgkin Lymphoma. <i>International Journal of Molecular Sciences</i> , 2014, 15, 6703-6716.	4.1	18
30	Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. <i>Annals of Hematology</i> , 2019, 98, 151-158.	1.8	18
31	Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 803.	2.6	18
32	The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-5.	1.9	17
33	High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 73-79.	2.0	17
34	Weekly rituximab consolidation following four cycles of CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). <i>European Journal of Haematology</i> , 2015, 94, 504-510.	2.2	16
35	First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. <i>Cancers</i> , 2020, 12, 2192.	3.7	16
36	Statistical Correlations Between Quantifiable Disease Variables and Prognosis in Hematological Malignancy Patients Treated with Itraconazole as An Empirical Antifungal Therapy: A Prospective Multicenter Observational Study in Korea. <i>Blood</i> , 2008, 112, 4028-4028.	1.4	16

#	ARTICLE	IF	CITATIONS
37	<i>In vitro</i> induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer. <i>Experimental and Molecular Medicine</i> , 2012, 44, 60.	7.7	15
38	Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 389-394.	0.4	15
39	Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. <i>Blood Research</i> , 2015, 50, 242.	1.3	15
40	Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. <i>Annals of Hematology</i> , 2016, 95, 625-635.	1.8	15
41	Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study. <i>Oncotarget</i> , 2017, 8, 68583-68590.	1.8	15
42	Polymyositis and myocarditis after donor lymphocyte infusion. <i>International Journal of Hematology</i> , 2009, 90, 113-116.	1.6	14
43	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. <i>Oncotarget</i> , 2016, 7, 72033-72043.	1.8	14
44	Induction Treatment With Cyclophosphamide, Thalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Phase II Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 62-67.	0.4	13
45	Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins. <i>Annals of Hematology</i> , 2011, 90, 1419-1426.	1.8	13
46	Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1205-1208.	2.4	13
47	A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. <i>British Journal of Haematology</i> , 2018, 181, 707-710.	2.5	12
48	Phase II study of R ² CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	12
49	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92171-92182.	1.8	12
50	Frontline therapy for newly diagnosed patients with multiple myeloma. <i>Blood Research</i> , 2020, 55, S37-S42.	1.3	12
51	Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 807-811.	1.3	11
52	Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma. <i>BMC Cancer</i> , 2019, 19, 59.	2.6	11
53	Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing. <i>Bone Marrow Transplantation</i> , 2021, 56, 1159-1170.	2.4	10
54	Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma. <i>Leukemia Research</i> , 2016, 49, 80-87.	0.8	9

#	ARTICLE	IF	CITATIONS
55	The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. <i>Annals of Hematology</i> , 2016, 95, 1491-1501.	1.8	9
56	Prognostic value of the inverse platelet to lymphocyte ratio (IPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen. <i>Annals of Hematology</i> , 2016, 95, 55-61.	1.8	9
57	Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	8
58	Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients. <i>Journal of Korean Medical Science</i> , 2016, 31, 1160.	2.5	8
59	A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2274-2284.	6.4	8
60	Tumor necrosis and complete resection has significant impacts on survival in patients with limited-stage upper aerodigestive tract NK/T cell lymphoma. <i>Oncotarget</i> , 2017, 8, 79337-79346.	1.8	8
61	Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. <i>Annals of Hematology</i> , 2016, 95, 603-611.	1.8	7
62	Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). <i>BMC Cancer</i> , 2018, 18, 729.	2.6	6
63	Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. <i>Annals of Hematology</i> , 2020, 99, 223-228.	1.8	6
64	Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era. <i>Scientific Reports</i> , 2020, 10, 11649.	3.3	6
65	RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. <i>Scientific Reports</i> , 2020, 10, 20119.	3.3	6
66	A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1599-1601.	10.5	6
67	5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 8305-8314.	1.8	6
68	Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). <i>Oncotarget</i> , 2017, 8, 13367-13374.	1.8	6
69	Development of a UPLC-MS/MS method for the therapeutic monitoring of L-asparaginase. <i>Translational and Clinical Pharmacology</i> , 2018, 26, 134.	0.9	5
70	Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas. <i>Annals of Hematology</i> , 2020, 99, 83-91.	1.8	5
71	The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 1169-1181.	1.7	5
72	Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea. <i>Journal of Korean Medical Science</i> , 2014, 29, 61.	2.5	4

#	ARTICLE	IF	CITATIONS
73	Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. <i>Annals of Hematology</i> , 2016, 95, 1645-1651.	1.8	4
74	A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 1406-1412.	1.3	4
75	A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). <i>Leukemia and Lymphoma</i> , 2019, 60, 3251-3257.	1.3	4
76	Nilotinib Combined With Multi-Agent Chemotherapy For Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Final Results Of Prospective Multicenter Phase 2 Study. <i>Blood</i> , 2013, 122, 55-55.	1.4	4
77	Relapse in patients with limited-stage ocular adnexal lymphoma treated by chemoimmunotherapy: Extended follow-up of a phase 2 study. <i>Cancer Medicine</i> , 2022, , .	2.8	4
78	Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	4
79	Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09). <i>Annals of Hematology</i> , 2020, 99, 2831-2836.	1.8	3
80	Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma. <i>In Vivo</i> , 2020, 34, 2127-2134.	1.3	3
81	Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea. <i>Blood Research</i> , 2021, , .	1.3	3
82	Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 149-156.	0.4	2
83	Adrenal insufficiency in hospitalized patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 501-503.	1.3	2
84	Clinical characteristics and prognostic factors of acquired haemophilia A in Korea. <i>Haemophilia</i> , 2021, 27, e609-e616.	2.1	2
85	Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience. <i>Radiation Oncology Journal</i> , 2017, 35, 317-324.	1.5	2
86	Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. <i>Yonsei Medical Journal</i> , 2020, 61, 452.	2.2	2
87	Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Korean Medical Science</i> , 2022, 37, e2.	2.5	2
88	Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. <i>Cancer Research and Treatment</i> , 2023, 55, 325-333.	3.0	2
89	Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma. <i>Chonnam Medical Journal</i> , 2015, 51, 109.	0.9	1
90	Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment. <i>Blood Research</i> , 2015, 50, 167.	1.3	1

#	ARTICLE	IF	CITATIONS
91	Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma. <i>Blood Research</i> , 2016, 51, 285.	1.3	1
92	Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone. <i>Experimental Hematology</i> , 2019, 75, 26-30.	0.4	1
93	Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 2310.	2.4	1
94	Clinical impact of cell-free serum Epstein-Barr virus status in patients with newly diagnosed malignant lymphoma. <i>Blood Research</i> , 2021, 56, 65-71.	1.3	1
95	Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18F-FDG PET/CT at Baseline. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
96	Comparing Standard IPI with Revised-IPI in Patients with Diffuse Large B-Cell Lymphoma: Which Has a More Differential Potential for Predicting the Outcomes after R-CHOP Chemotherapy.. <i>Blood</i> , 2008, 112, 2003-2003.	1.4	1
97	Lymphocytopenia Is Associated with an Increased Risk of Severe Infections in Patients with Multiple Myeloma Treated with Bortezomib-Based Regimens. <i>Blood</i> , 2012, 120, 5042-5042.	1.4	1
98	Serum Level Of Parathyroid Hormone Is Associated With Risk Factors and Clinical Outcomes In Multiple Myeloma. <i>Blood</i> , 2013, 122, 5365-5365.	1.4	1
99	Comparison of the Peripheral Blood Stem Cell Mobilization and Harvest after Each Consolidation Chemotherapy in Patients with Acute Myeloid Leukemia in First Complete Remission Who Underwent Autologous Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 5495-5495.	1.4	1
100	Phase II Trial of 90y-Ibritumomab Tiuxetan Treatment as Consolidation After 6th R-CHOP Chemotherapy in Patients with Limited-Stage, Bulky Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3751-3751.	1.4	1
101	A Modified Glasgow Prognostic Score (mGPS) Based On Systemic Inflammatory Response Is a Useful Indicator to Predict Response and Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2012, 120, 5089-5089.	1.4	1
102	Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL). <i>Cancer Research and Treatment</i> , 2023, 55, 304-313.	3.0	1
103	Clinical Correlation of CD4+CD25+ Regulatory T Cells in Early Immune Reconstitution after Myeloablative Allogeneic Stem Cell Transplantation. <i>Chonnam Medical Journal</i> , 2009, 45, 154.	0.1	0
104	Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e529-e535.	0.4	0
105	Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment. <i>International Journal of Hematology</i> , 2021, 113, 668-674.	1.6	0
106	Clinical Significance of FLT3 Internal Tandem Duplication in Patients with Acute Myeloid Leukemia Who Underwent Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , 2004, 104, 4419-4419.	1.4	0
107	Predictable Prognostic Factor of CD56 Expression in Acute Myeloid Leukemia with t(8:21) Including Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 3288-3288.	1.4	0
108	Methylenetetrahydrofolate Reductase and Methionine Synthase Polymorphism and Risk of Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2005, 106, 4691-4691.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Modified Thalidomide, Cyclophosphamide and Dexamethasone (TCD) to Patients with Multiple Myeloma as Primary Therapy Prior to Peripheral Blood Stem Cell Collection.. Blood, 2005, 106, 5173-5173.	1.4	0
110	Clinical Usefulness and Therapeutic Plan with Interim PET/CT Analysis in Malignant Lymphoma.. Blood, 2006, 108, 2403-2403.	1.4	0
111	Clinical Correlation of Foxp3 Regulatory Gene Expressions and NK Cells in Early Engraftment after Myeloablative Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 2911-2911.	1.4	0
112	No Reversal of Demethylation after Azacitidine Treatment in Concordance with Poor Clinical Response.. Blood, 2007, 110, 4629-4629.	1.4	0
113	Central Nervous System Relapses in Patients with Diffuse Large B Cell Lymphoma: Multicenter Retrospective Analysis in Korea. Blood, 2008, 112, 5314-5314.	1.4	0
114	Polymorphisms in Myeloid Cell Leukemia-1 and the Risk for Acute Myeloid Leukemia. Blood, 2008, 112, 3977-3977.	1.4	0
115	GST T1 and GST M1 Polymorphisms Are Associated with the Risk of Acute Myeloid Leukemia. Blood, 2008, 112, 3978-3978.	1.4	0
116	Alpha-Type 1-Polarized Dendritic Cells Pulsed with Apoptotic Allogeneic Myeloma Cell Line Could Induce the Strong CTL Responses against Autologous Myeloma Cells.. Blood, 2009, 114, 4931-4931.	1.4	0
117	Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases.. Blood, 2009, 114, 4661-4661.	1.4	0
118	Relapsed Marginal Zone B-Cell Lymphoma: Clinical Features and Treatment Outcome.. Blood, 2009, 114, 5017-5017.	1.4	0
119	Treatment Outcome of Steroid-Refractory Chronic Graft-Versus-Host Disease with Weekly Rituximab Followed by Maintenance Rituximab: a KSBMT Multicenter Phase II Study.. Blood, 2009, 114, 1151-1151.	1.4	0
120	Association Between Genetic Polymorphism in DNA Repair Genes and Acute Myeloid Leukemia.. Blood, 2009, 114, 4131-4131.	1.4	0
121	Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers. Blood, 2011, 118, 1866-1866.	1.4	0
122	Potent Immunomodulatory Drug Lenalidomide Synergistically Enhance the Effect of Dendritic Cell Vaccination on Multiple Myeloma in Mouse Model,. Blood, 2011, 118, 3237-3237.	1.4	0
123	High Dose Etoposide Plus G-CSF As an Effective Mobilization Regimen in Patients with NHL Previously Treated with R-CHOP or CHOP Chemotherapy. Retrospective Multicenter Study. Blood, 2012, 120, 1917-1917.	1.4	0
124	Clinical significance of radiotherapy in the treatment of limited stage NK/T cell lymphoma.. Journal of Clinical Oncology, 2015, 33, 8549-8549.	1.6	0
125	5-Hydroxymethylcytosine Is Correlated with TET2 or IDH1/2 Mutations However, May Not be a Prognostic Value to Predict the Survivals in Normal Karyotype AML. Blood, 2015, 126, 3832-3832.	1.4	0
126	Discrepancy of Interim PET/CT Responses Based on Visual and Quantitative SUV-Based Assessments in the Patients with Diffuse Large B-Cell Lymphoma and Extranodal Involvements. Blood, 2015, 126, 1446-1446.	1.4	0

#	ARTICLE	IF	CITATIONS
127	In the Novel Agents Era, Is the International Staging System Still Has the Prognostic Value in Patients with Renal Impairment?. Blood, 2015, 126, 5313-5313.	1.4	0
128	Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype. Blood, 2016, 128, 2876-2876.	1.4	0
129	A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial. Blood, 2016, 128, 1823-1823.	1.4	0
130	Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 CD20+ Diffuse Large B-Cell Lymphoma (CISL 12-09). Blood, 2016, 128, 4193-4193.	1.4	0
131	18f-FDG PET/CT and the Revised International Staging System Are More Discriminating of Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 4483-4483.	1.4	0
132	Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era. Blood, 2019, 134, 4002-4002.	1.4	0
133	Variant Allele Frequency Status in Elderly Patients with Acute Myeloid Leukemia Can be Early Predictors of Responsiveness to Decitabine Treatment. Blood, 2021, 138, 3450-3450.	1.4	0